CLINICAL TRIALS PROFILE FOR CROFELEMER
✉ Email this page to a colleague
All Clinical Trials for Crofelemer
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00002186 ↗ | Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS) | Completed | Shaman Pharmaceuticals | N/A | 1969-12-31 | To evaluate the safety of topically applied SP-303 gel and to compare the efficacy of SP-303 gel in combination with acyclovir, relative to acyclovir alone, for the treatment of recurrent Herpes Simplex Virus (HSV) 1 and 2 infections, affecting the genital, perianal and neighboring areas, in patients with AIDS. |
NCT00002310 ↗ | SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir | Completed | Shaman Pharmaceuticals | N/A | 1969-12-31 | To evaluate the safety and tolerance of topically applied SP-303T in AIDS patients. To observe the effect of this drug on herpes simplex virus lesions in patients who have failed to heal in response to oral or intravenous acyclovir therapy. The lack of alternative treatments for herpes simplex virus infection in patients with AIDS and the development of resistance to acyclovir for patients requiring repeated treatment presents a therapeutic dilemma for physicians. SP-303T has good in vitro activity against resistant strains and offers a convenient and inexpensive means of drug administration in comparison to the use of intravenous medication. |
NCT00002408 ↗ | A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) Patients | Completed | Shaman Pharmaceuticals | Phase 3 | 1969-12-31 | To evaluate the efficacy, safety, and durability of response of SP-303 in decreasing stool weight in AIDS patients with diarrhea over 6 days of treatment. |
NCT00101725 ↗ | A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome | Completed | Bausch Health Americas, Inc. | Phase 2 | 2004-12-01 | This study is designed to evaluate the safety and effectiveness of an investigational drug, TRN-002 (crofelemer) to relieve the symptoms of diarrhea-predominant irritable bowel syndrome (IBS). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Crofelemer
Condition Name
Clinical Trial Locations for Crofelemer
Trials by Country
Clinical Trial Progress for Crofelemer
Clinical Trial Phase
Clinical Trial Sponsors for Crofelemer
Sponsor Name